{"id":18422,"date":"2015-10-08T15:10:00","date_gmt":"2015-10-08T15:10:00","guid":{"rendered":"http:\/\/localhost\/sccblog\/?p=18422"},"modified":"2015-10-16T16:58:21","modified_gmt":"2015-10-16T11:28:21","slug":"glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","title":{"rendered":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs"},"content":{"rendered":"

Delhi<\/span><\/b> High Court<\/span><\/b>: In granting permanent injunction to US drug company Merck Sharp and Dohme (MSD), the Court restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs “Zita” and “Zita-Met”, saying it has infringed patent of the plaintiff. The US drug maker in its plea had sought injunction against Glenmark alleging it of violating its patent rights. The plaintiff sells its anti-diabetic product in India under the brand name “Januvia” and “Janumeta”. <\/span><\/p>\n

The patent dispute arose in the year 2013 when the plaintiff moved against the defendant, alleging patent infringement. The invention of plaintiffs (MSD), that is, Sitagliptin improves the efficient management of the condition of a patient suffering from type II diabetes by inhibiting the DPP-IV enzyme According to the plaintiff, Sitagliptin phosphate monohydrate, the main component of defendant\u2019s drugs, could not be made without manufacturing the active molecule Sitagliptin, “invented and patented” by the US drug maker.\u00a0 In reply to this the defendant said, “Sitagliptin\u00a0 is not the only DPP-IV inhibitor (oral anti-diabetes drug) for treatment of type II diabetes in the market and there are several other DPP-IV inhibitors, including the one manufactured and marketed by the defendant, that is, Teneligliptin”. Further, they argued that Sitagliptin Phosphate Monohydrate as also the combination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride are totally different than the Sitagliptin Hydrochloride salt. It was also contended that the process followed by the defendant for production of Zita and Zita-met is completely different than the process of manufacturing followed by the plaintiff.<\/span><\/p>\n

A K Pathak, J. while permanently injuncting the defendant from making and selling the two drugs said, <\/span>“it emerges from the comparison of the product inserts of the plaintiffs\u2019 product and that of the defendant that they are the same and contain the same compound, that is, sitagliptin phosphate monohydrate.” \u00a0The court remarked that, there was no public interest in the matter as there were other chemical compounds, other than the one invented by the plaintiff, which were used in anti-diabetes drugs.\u00a0 However, on defendant’s oral plea to allow it to sell its goods already in the market, clarified that it “may sell such of the products which are already in the market i.e in possession of its distributors and retailers”. [Merck Sharp and Dohme Corpn. v. Glenmark Pharmaceuticals Ltd.,<\/i><\/span>2015 SCC OnLine Del 12580<\/a>,\u00a0Decided on 7-10-2015]<\/p>\n","protected":false},"excerpt":{"rendered":"

Delhi High Court: In granting permanent injunction to US drug company Merck Sharp and Dohme (MSD), the Court restrained Indian firm Glenmark <\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3,10],"tags":[],"class_list":["post-18422","post","type-post","status-publish","format-standard","hentry","category-casebriefs","category-highcourts"],"yoast_head":"\nGlenmark restrained from manufacturing and selling its anti-diabetes drugs | SCC Times<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glenmark restrained from manufacturing and selling its anti-diabetes drugs\" \/>\n<meta property=\"og:description\" content=\"Delhi High Court: In granting permanent injunction to US drug company Merck Sharp and Dohme (MSD), the Court restrained Indian firm Glenmark\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-08T15:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-10-16T11:28:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1329\" \/>\n\t<meta property=\"og:image:height\" content=\"888\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sucheta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sucheta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/\",\"name\":\"Glenmark restrained from manufacturing and selling its anti-diabetes drugs | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"datePublished\":\"2015-10-08T15:10:00+00:00\",\"dateModified\":\"2015-10-16T11:28:21+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glenmark restrained from manufacturing and selling its anti-diabetes drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa\",\"name\":\"Sucheta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g\",\"caption\":\"Sucheta\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/legal_editor\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs | SCC Times","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","og_locale":"en_US","og_type":"article","og_title":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs","og_description":"Delhi High Court: In granting permanent injunction to US drug company Merck Sharp and Dohme (MSD), the Court restrained Indian firm Glenmark","og_url":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2015-10-08T15:10:00+00:00","article_modified_time":"2015-10-16T11:28:21+00:00","og_image":[{"width":1329,"height":888,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg","type":"image\/jpeg"}],"author":"Sucheta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sucheta","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","url":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","name":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"datePublished":"2015-10-08T15:10:00+00:00","dateModified":"2015-10-16T11:28:21+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa"},"breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa","name":"Sucheta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g","caption":"Sucheta"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/legal_editor\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":296078,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/07\/05\/delhi-high-court-grants-injunction-to-sun-pharma-for-its-mark-instamet-legal-news\/","url_meta":{"origin":18422,"position":0},"title":"Delhi High Court restrains Glemark Pharmaceuticals from using \u201cINDAMET\u201d mark; grants injunction to Sun Pharma for its mark \u201cINSTAMET\u201d","author":"Simranjeet","date":"July 5, 2023","format":false,"excerpt":"The two competing marks \u201cISTAMET\u201d and \u201cINDAMET\u201d are clearly structurally and phonetically similar, and when seen from the eyes of consumer of average intelligence having imperfect recollection, there are high chances of confusion and deception. Confusion surrounding the mode of administration of a drug can lead to misuse and potential\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":324619,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/06\/18\/bhc-grants-ad-interim-injunction-to-glenmark-pharmaceuticals-for-mark-zitamet\/","url_meta":{"origin":18422,"position":1},"title":"\u2018Ordinary common man will be confused\u2019; Bombay HC grants ad-interim injunction to Glenmark Pharmaceuticals for mark \u201cZITA-MET\u201d against Gleck Pharma\u2019s mark \u201cXIGAMET\u201d","author":"Simranjeet","date":"June 18, 2024","format":false,"excerpt":"The Court stated that physicians, doctors, and chemists are knowledgeable in their field, however they are not infallible, and in respect of medicinal and pharmaceutical products there cannot be any leeway for mistakes, since even a possibility of a mistake may prove fatal to the consumers.","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Bombay High Court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Bombay-High-Court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Bombay-High-Court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Bombay-High-Court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Bombay-High-Court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":296408,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/07\/10\/delhi-hc-denies-interim-injunction-to-bayer-healthcare-for-drug-regorafenib-legal-news\/","url_meta":{"origin":18422,"position":2},"title":"\u2018Public interest demands easy, affordable access to anti-cancer drug\u2019; Delhi High Court denies interim injunction to Bayer Healthcare for drug \u2018Regorafenib\u2019","author":"Simranjeet","date":"July 10, 2023","format":false,"excerpt":"Bayer healthcare LLC was selling its product of Rs. 36,995 by importing the same into India, whereas the Natco Pharma Ltd. was manufacturing the product in India and selling the same of Rs. 9,900. The injunction was refused due to the huge disparity between the prices offered by both, for\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":325977,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/07\/07\/top-intellectual-property-cases-june-2024-legal-news\/","url_meta":{"origin":18422,"position":3},"title":"Intellectual Property Rights | A quick view of top Intellectual Property cases in June 2024","author":"Editor","date":"July 7, 2024","format":false,"excerpt":"A quick recap of Intellectual Property cases passed by the High Courts in the month of June 2024 along with some top stories on Domino\u2019s, Infosys Trademark Infringement, Patent for Portable Vehicle Management System and much more.","rel":"","context":"In "Legal RoundUp"","block_context":{"text":"Legal RoundUp","link":"https:\/\/www.scconline.com\/blog\/post\/category\/columns-for-roundup\/"},"img":{"alt_text":"Intellectual Property cases Roundup June 2024","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/07\/Intellectual-Property-cases-Roundup-June-2024.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":299984,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/08\/24\/delhi-hc-modifies-patent-injunction-to-extent-honeycomb-panels-are-for-supply-to-ministry-of-defence\/","url_meta":{"origin":18422,"position":4},"title":"Delhi High Court modifies patent injunction to the extent honeycomb panels are for supply to the Ministry of Defence","author":"Simranjeet","date":"August 24, 2023","format":false,"excerpt":"\u201cThe defendant is selling honeycomb panels to the Ministry of Defence since 2012 and containers of the defendant cannot be sold without the panel, considering the purpose for which containers are stated to be needed, that too by the Ministry of Defence.\u201d","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":27731,"url":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","url_meta":{"origin":18422,"position":5},"title":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company","author":"Sucheta","date":"November 30, 2015","format":false,"excerpt":"Delhi High Court: While addressing to the issue of patent violation, the Court concluded that Cipla (Defendant) was infringing on Swiss pharmaceutical company Hoffman-La Roche's (Plaintiff) patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva. Cipla\u2019s drug named Erlocip, used for treatment of non-small cell lung\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/18422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=18422"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/18422\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=18422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=18422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=18422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}